700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Research Paper Open Access
As glibenclamide is metabolised completely in the liver, the principal metabolite being only very weakly active, buccal strip glibenclamide may be very useful for the treatment of diabetes more efficiently. The objective of this work is to investigate the possibility of obtaining a slow release, relatively constant effective levels of glibenclamide from buccal strips using chitosan. Here attempts were made to develop suitable chitosan-based buccal strips and to characterise it using different in vitro methods. Chitosan- based strips of glibenclamide showed suitability over Eudragit-based glibenclamide buccal strips for controlled release behaviour.
To read the full article Peer-reviewed Article PDF
Author(s): R Ilango S Kavimani A R Mullaicharam B Jayakar